Curon Medical
This article was originally published in The Gray Sheet
Executive Summary
Initial public offering proceeds increase to $60.2 mil. following exercise of 475,000-share overallotment option, announced Oct. 14. The Sunnyvale, California maker of the Stretta radiofrequency system for gastroesophageal reflux disease initially went public Sept. 22 via an offering of 5 mil. shares at $11 each (1"The Gray Sheet" Oct. 2, 2000, p. 16). A portion of the proceeds will be used to build up the company's sales force for marketing the Stretta system, cleared by FDA via 510(k) in April. Underwriters included lead manager UBS Warburg LLC and co-managers CIBC World Markets and SG Cowen